Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Melitracen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.94 |
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.94 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.94 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.94 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.56 |
| ▸ | HRH1 | P35367 | 8/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.94 |
| ▸ | HTR2B | P41595 | 6/20 | 0.94 |
| ▸ | DRD2 | P14416 | 6/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.94 |
| ▸ | DRD3 | P35462 | 6/20 | 0.94 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.94 |
| ▸ | HTR2A | P28223 | 5/20 | 0.94 |
| ▸ | HTR2C | P28335 | 5/20 | 0.94 |
| ▸ | HTR1A | P08908 | 5/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.94 |
| ▸ | DRD1 | P21728 | 4/20 | 0.94 |
| ▸ | MC3R | P41968 | 4/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melitracen SCHEMBL48975 | 0.97 | HRH1 (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL29984590 | 0.97 | HRH1 (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL121493 | 0.95 | HRH1 (0.97) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL2473296 | 0.95 | HRH1 (0.97) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL29399425 | 0.95 | HRH1 (0.97) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL29195738 | 0.94 | HRH1 (0.94) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Cyclobenzaprine SCHEMBL1649752 | 0.78 | HRH1 (0.93) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Amitriptyline SCHEMBL3055149 | 0.76 | SLC6A2 (0.94) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Litracen SCHEMBL2109078 | 0.74 | SLC6A2 (0.62) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Cyclobenzaprine SCHEMBL29520569 | 0.73 | HRH1 (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-115417753-B | Synthesis method of melitracen and intermediate thereof | 重庆西南制药二厂有限责任公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-115417753-A | Synthetic method of melitracen and intermediate thereof | 重庆西南制药二厂有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-114057586-A | Melletoxin hydrochloride crystal form A and preparation method thereof | 江苏恩华药业股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-8629135-B2 | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-01-14 | — | — | US | disclosed |
| US-20110201598-A1 | Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer | GUJRAL, TARANJIT S. | 2011-08-18 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201598-A1 | Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer | RET, THRB, SKP1 | SLC6A2 3547/4885CHRM2 1433/4885CHRM1 1639/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | SLC6A2 804/4885CHRM2 880/4885CHRM1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.